In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination.

Andrew J FratoniLindsay M AveryYasmeen Abouelhassan Tomefa E Asempa

Published in: The Journal of antimicrobial chemotherapy (2022)

Ledaborbactam fAUC0-24/MIC exposures for stasis were quantified with a ceftibuten human-simulated regimen against β-lactamase-producing Enterobacterales. This study supports the continued development of oral ceftibuten/ledaborbactam etzadroxil (formerly ceftibuten/VNRX-7145).

Keyphrases

endothelial cells
escherichia coli
gram negative
air pollution
multidrug resistant
klebsiella pneumoniae